Literature DB >> 9230261

Pleurodesis: state of the art.

F Rodriguez-Panadero1, V B Antony.   

Abstract

Pleurodesis aims to achieve a symphysis between parietal and visceral pleural surfaces, in order to prevent accumulation of fluid or air in the pleural space. Its major indications are malignant effusions and pneumothorax, and a re-expandable lung is essential for the success of the technique. Moreover, expectation of a reasonably long survival is important before attempting pleurodesis. A successful lung re-expansion is unlikely if the pleural pressure falls more than 20 cmH2O x L(-1) of fluid removed, because there is a central bronchial obstruction or the lung is trapped by tumour and/or fibrin. Pleural fluid pH (<7.20) is a good indicator of the presence of trapped lung; moreover, a successful pleurodesis is less likely when pH is low, and this parameter is also a good predictor for survival of the patients. Among the many sclerosing agents that have been used for pleurodesis, talc has achieved the best results, with an average success rate of approximately 90%. The cellular and biochemical mechanisms involved in pleurodesis may be specific to the agent used, however, they may all follow a common final pathway leading to activation of the pleural coagulation cascade, the appearance of fibrin networks, and the proliferation of fibroblasts. The details of these mechanisms are still unclear and need to be further elaborated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230261     DOI: 10.1183/09031936.97.10071648

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  23 in total

Review 1.  The pleural cavity.

Authors:  G J Peek; S Morcos; G Cooper
Journal:  BMJ       Date:  2000-05-13

2.  Treating hepatic hydrothorax.

Authors:  Jakob Borchardt; Alona Smirnov; Lora Metchnik; Stephen Malnick
Journal:  BMJ       Date:  2003-04-05

3.  Tube thoracostomy: a review for the interventional radiologist.

Authors:  Jeremy R Hogg; Michael Caccavale; Benjamin Gillen; Gavin McKenzie; Jay Vlaminck; Chad J Fleming; Andrew Stockland; Jeremy L Friese
Journal:  Semin Intervent Radiol       Date:  2011-03       Impact factor: 1.513

4.  Hepatic hydrothorax in the absence of ascites.

Authors:  Kittiya Sukcharoen; Steven Dixon; Kamarjit Mangat; Andrew Stanton
Journal:  BMJ Case Rep       Date:  2013-09-11

5.  Rapid pleurodesis is an outpatient alternative in patients with malignant pleural effusions: a prospective randomized controlled trial.

Authors:  Serkan Özkul; Akif Turna; Ahmet Demirkaya; Burcu Aksoy; Kamil Kaynak
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

6.  Clinical-therapeutic management of thoracoscopy in pleural effusion: a groundbreaking technique in the twenty-first century.

Authors:  José Marcelo Galbis; Manuel Mata; Ricardo Guijarro; Rafael Esturi; Salvador Figueroa; Antonio Arnau
Journal:  Clin Transl Oncol       Date:  2011-01       Impact factor: 3.405

7.  Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study.

Authors:  Marta Korsic; Sonja Badovinac; Branka Cucevic; Zoran Janevski
Journal:  Wien Klin Wochenschr       Date:  2015-04-10       Impact factor: 1.704

8.  Increased pleural fluid adenosine deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome.

Authors:  Huseyin Yildirim; Muzaffer Metintas; Güntülü Ak; Sinan Erginel; Fusun Alatas; Emel Kurt; Selma Metintas; Irfan Ucgun
Journal:  Lung       Date:  2007-10-19       Impact factor: 2.584

9.  Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial.

Authors:  Fabio José Haddad; Riad Naim Younes; Jefferson Luiz Gross; Daniel Deheinzelin
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

10.  Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(®) Injection) for Malignant Pleural Effusion.

Authors:  Jeong Su Cho; Kook Joo Na; Yongjik Lee; Yeong Dae Kim; Hyo Yeong Ahn; Chang Ryul Park; Young Chul Kim
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-12-04       Impact factor: 1.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.